Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Current Leases (2021 - 2026)

Enliven Therapeutics has reported Current Leases over the past 6 years, most recently at $302000.0 for Q1 2026.

  • Quarterly results put Current Leases at $302000.0 for Q1 2026, down 17.26% from a year ago — trailing twelve months through Mar 2026 was $302000.0 (down 17.26% YoY), and the annual figure for FY2025 was $399000.0, changed.
  • Current Leases reached $302000.0 in Q1 2026 per ELVN's latest filing, down from $399000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $508000.0 in Q1 2022 and bottomed at $85000.0 in Q3 2024.
  • Median Current Leases over the past 5 years was $333500.0 (2023), compared with a mean of $329071.4.
  • The largest annual shift saw Current Leases tumbled 74.4% in 2024 before it skyrocketed 355.29% in 2025.
  • Over 5 years, Current Leases stood at $323000.0 in 2022, then rose by 3.72% to $335000.0 in 2023, then crashed by 74.63% to $85000.0 in 2024, then skyrocketed by 369.41% to $399000.0 in 2025, then dropped by 24.31% to $302000.0 in 2026.
  • Business Quant data shows Current Leases for ELVN at $302000.0 in Q1 2026, $399000.0 in Q4 2025, and $387000.0 in Q3 2025.